Vivos Therapeutics, Inc. (VVOS)
VVOS moved a median of -0.36% 30 minutes after news, and -1.01% by the close. How VVOS actually reacts to news — the realized, point-in-time move the market made, measured across 219 labeled events over the last three years with zero look-ahead.
VVOS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.25% | 39% | 209 |
| 30-min | -0.36% | 39% | 216 |
| 60-min | -0.12% | 41% | 216 |
| to close | -1.01% | 43% | 212 |
| Middle 50% of VVOS reactions | -3.23% to +1.68% |
|---|---|
| Median reaction (30-min) | -0.36% |
| Measured reactions | 219 |
Half of all Vivos Therapeutics, Inc. news events land between -3.23% and +1.68% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VVOS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VVOS's baseline. Nothing else.
Recent VVOS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test | Press release | ACCESS Newswire | -0.08% | +10.80% | |
| Form 8-K Vivos Therapeutics, Inc. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | -2.60% | +7.58% | |
| Form PRE 14A Vivos Therapeutics, Inc. For: Oct 19 | SEC filing · Form PRE | SEC EDGAR | -2.60% | +7.58% | |
| Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel | Press release | GlobeNewswire | -2.60% | +7.58% | |
| Form 8-K Vivos Therapeutics, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -3.67% | +5.93% | |
| Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test | Press release | GlobeNewswire | -3.67% | +5.93% | |
| Form 8-K Vivos Therapeutics, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +3.47% | |
| Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives | Press release | GlobeNewswire | -1.40% | +8.35% | |
| Form 8-K Vivos Therapeutics, Inc. For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +2.31% | -1.37% | |
| Form 8-K/A Vivos Therapeutics, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +0.60% | +1.61% | |
| Vivos Therapeutics Announces Material Debt Reduction | Press release | GlobeNewswire | +2.31% | -1.37% | |
| Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center | Press release | GlobeNewswire | -1.37% | -11.80% | |
| Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers | Press release | GlobeNewswire | -3.73% | -5.76% | |
| Form 8-K Vivos Therapeutics, Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -5.60% | -7.73% | |
| Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment | Press release | GlobeNewswire | -1.77% | +0.02% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.31% | +0.07% | |
| Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update | Press release | GlobeNewswire | +6.31% | +0.07% | |
| Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call | Press release | GlobeNewswire | -0.58% | +11.71% | |
| Form 8-K Vivos Therapeutics, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -4.47% | -7.32% | |
| Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations | Press release | GlobeNewswire | +1.18% | -5.21% | |
| Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology | Press release | GlobeNewswire | +8.87% | +9.87% | |
| Form 8-K Vivos Therapeutics, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | +8.75% | |
| Form 8-K Vivos Therapeutics, Inc. For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -2.71% | +3.31% | |
| Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants | Press release | GlobeNewswire | -16.65% | -15.83% | |
| Form 8-K Vivos Therapeutics, Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.85% | |
| Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity | Press release | GlobeNewswire | +1.13% | -17.07% | |
| Form 8-K Vivos Therapeutics, Inc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -3.80% | |
| Form 8-K Vivos Therapeutics, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +2.28% | -3.55% | |
| Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering | Press release | GlobeNewswire | -5.83% | -8.27% | |
| Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients | Press release | GlobeNewswire | +0.24% | -7.43% | |
| Form 8-K Vivos Therapeutics, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -1.52% | +6.10% | |
| Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 | Press release | GlobeNewswire | -0.66% | -0.66% | |
| Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing | Press release | GlobeNewswire | -0.67% | +19.23% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.37% | +0.83% | |
| Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update | Press release | GlobeNewswire | +1.37% | +0.83% | |
| Form NT 10-Q Vivos Therapeutics, Inc. For: Mar 31 | SEC filing · Form NT | SEC EDGAR | -1.57% | -6.70% | |
| Form EFFECT Vivos Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.00% | -0.06% | |
| Form S-3/A Vivos Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.18% | +0.33% | |
| Form 8-K Vivos Therapeutics, Inc. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | -4.76% | -14.68% | |
| Form 10-K Vivos Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.42% | -12.10% | |
| Form 8-K Vivos Therapeutics, Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +2.42% | -12.10% | |
| Vivos Therapeutics Reports Full Year 2025 Financial Results | Press release | GlobeNewswire | +2.42% | -12.10% | |
| Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call | Press release | GlobeNewswire | -0.74% | +8.89% | |
| Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners | Press release | GlobeNewswire | — | +3.33% | |
| Form 8-K Vivos Therapeutics, Inc. For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -6.43% | |
| Form NT 10-K Vivos Therapeutics, Inc. For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -1.71% | +11.11% | |
| Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market | Press release | GlobeNewswire | -0.89% | +5.31% | |
| Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy | Press release | GlobeNewswire | +1.54% | +1.54% | |
| Form S-3 Vivos Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -1.33% | +5.33% | |
| New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST) | Press release | ACCESS Newswire | -1.33% | +5.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VVOS section they belong to.
Where else VVOS is measured.
VVOS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Vivos Therapeutics, Inc.'s median reaction calculated?
Every labeled VVOS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 219 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of VVOS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VVOS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.